Switch theme
Sign up to access all valuation multiples
Dr Agarwal’s Health Care Ltd is engaged in eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lenses and accessories, and eye care related pharmaceutical products. It offer services such as Surgeries, Cataract surgeries, Refractive surgeries, Other surgeries, and Consultations, diagnoses and non-surgical treatments, Its products services include Sale of opticals and Sale of eye care-related pharmaceutical products. The company is engaged in single segment that is eye care and related services provided from its hospitals which are located in India and Africa.
2010
6.3K+
LTM Revenue $207M
LTM EBITDA $55.3M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dr Agarwals has a last 12-month revenue (LTM) of $207M and a last 12-month EBITDA of $55.3M.
In the most recent fiscal year, Dr Agarwals achieved revenue of $122M and an EBITDA of $42.1M.
Dr Agarwals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dr Agarwals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $207M | XXX | $122M | XXX | XXX | XXX |
| Gross Profit | $160M | XXX | $50.6M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $55.3M | XXX | $42.1M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $27.7M | XXX | $10.4M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $10.6M | XXX | $2.6M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $16.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dr Agarwals's stock price is INR 338 (or $4).
Dr Agarwals has current market cap of INR 107B (or $1.3B), and EV of INR 111B (or $1.3B).
See Dr Agarwals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.3B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dr Agarwals has market cap of $1.3B and EV of $1.3B.
Dr Agarwals's trades at 9.9x EV/Revenue multiple, and 29.9x EV/EBITDA.
Equity research analysts estimate Dr Agarwals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dr Agarwals has a P/E ratio of 117.8x.
See valuation multiples for Dr Agarwals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBITDA | 23.5x | XXX | 29.9x | XXX | XXX | XXX |
| EV/EBIT | 46.9x | XXX | 94.6x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 117.8x | XXX | 287.6x | XXX | XXX | XXX |
| EV/FCF | -29.6x | XXX | 191.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDr Agarwals's last 12 month revenue growth is 21%
Dr Agarwals's revenue per employee in the last FY averaged $19K, while opex per employee averaged $6K for the same period.
Dr Agarwals's rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dr Agarwals's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dr Agarwals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 31% | XXX | XXX | XXX |
| Rule of 40 | 54% | XXX | 54% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 79% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $19K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $6K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr Agarwals acquired XXX companies to date.
Last acquisition by Dr Agarwals was XXXXXXXX, XXXXX XXXXX XXXXXX . Dr Agarwals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dr Agarwals founded? | Dr Agarwals was founded in 2010. |
| Where is Dr Agarwals headquartered? | Dr Agarwals is headquartered in India. |
| How many employees does Dr Agarwals have? | As of today, Dr Agarwals has 6.3K+ employees. |
| Is Dr Agarwals publicy listed? | Yes, Dr Agarwals is a public company listed on NSE. |
| What is the stock symbol of Dr Agarwals? | Dr Agarwals trades under AGARWALEYE ticker. |
| When did Dr Agarwals go public? | Dr Agarwals went public in 2025. |
| Who are competitors of Dr Agarwals? | Similar companies to Dr Agarwals include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Dr Agarwals? | Dr Agarwals's current market cap is $1.3B |
| What is the current revenue of Dr Agarwals? | Dr Agarwals's last 12 months revenue is $207M. |
| What is the current revenue growth of Dr Agarwals? | Dr Agarwals revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Dr Agarwals? | Current revenue multiple of Dr Agarwals is 6.3x. |
| Is Dr Agarwals profitable? | Yes, Dr Agarwals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dr Agarwals? | Dr Agarwals's last 12 months EBITDA is $55.3M. |
| What is Dr Agarwals's EBITDA margin? | Dr Agarwals's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Dr Agarwals? | Current EBITDA multiple of Dr Agarwals is 23.5x. |
| What is the current FCF of Dr Agarwals? | Dr Agarwals's last 12 months FCF is -$43.8M. |
| What is Dr Agarwals's FCF margin? | Dr Agarwals's last 12 months FCF margin is -21%. |
| What is the current EV/FCF multiple of Dr Agarwals? | Current FCF multiple of Dr Agarwals is -29.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
